TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19898966
Drug: Intravenous levetiracetam
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous levetiracetam (LEV)
Study: 10919601
Drug: Machine perfusion
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Machine perfusion (MP) in UW-machine perfusate solution (MPS)
Study: 3542325
Drug: Methylprednisolone sodium
Normalized name: methylPREDNISolone sodium phosphate
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone sodium succinate (250 mg)
Study: 3542325
Drug: Metoclopramide hydrochloride
Normalized name: Metoclopramide Hydrochloride
DrugBank: Metoclopramide (DB01233)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metoclopramide hydrochloride (10 mg)
Study: 30968534
Drug: Non-Chinese herbal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-Chinese herbal medicine users (controls)
Study: 30968534
Drug: Chinese herbal
Normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese herbal medicines (CHMs) for over 2 years
Study: 23134887
Drug: Multiple micronutrient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple micronutrient supplementation (vitamin B complex and vitamins C and E) among children whose mothers received ARV therapy
Study: 18822796
Drug: Hypnotic suggestions
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hypnotic suggestions of analgesia during different conditions (pre-hypnosis, neutral hypnosis, suggestions for analgesia, posthypnotic conditions)
Study: 18822796
Drug: Suggestions for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suggestions for analgesia administered after a mental stress instead of neutral hypnosis
Study: 18822796
Drug: Hypnotic relaxation
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hypnotic relaxation and suggestions of analgesia in healthy Lows receiving nociceptive stimulation
Study: 16040874
Drug: Asthma clubs
Normalized name: Hercules Club Whole
DrugBank: Zanthoxylum clava-herculis whole (DB14353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Asthma clubs intervention (weekly sessions over 8 weeks)
Study: 11778093
Drug: 0.5% levobupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% levobupivacaine (group L, n=22)
Study: 7819687
Drug: Vaginal douche
Normalized name: Rexall 0.3 % Vaginal Douche
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal douche with chlorhexidine solution (method I)
Study: 7819687
Drug: Chlorhexidine gluconate
Normalized name: Chlorhexidine Gluconate
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorhexidine gluconate obstetrical gel during vaginal exploration (method II)
Study: 8098520
Drug: Topical 1%
Normalized name: fluoride topical 1% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 1% apraclonidine
Study: 31608926
Drug: Cotadutide (50-300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cotadutide (50-300 µg, once-daily subcutaneous)
Study: 26863738
Drug: Etiotropic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etiotropic therapy with treatment and rehabilitation measures
Study: 26863738
Drug: Etiotropic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etiotropic therapy alone
Study: 9395384
Drug: Weekly chloroquine
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly chloroquine
Study: 16899213
Drug: Self-help based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-help based on cognitive behaviour therapy with Internet support
Study: 3046630
Drug: Urapidil (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urapidil (30 to 90 mg bid)
Study: 3046630
Drug: Captopril (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (12.5 to 50 mg bid)
Study: 28770459
Drug: liraglutide 1.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: liraglutide 1.8 mg once daily for 24 weeks
Study: 23623012
Drug: Phytosterol capsules
Normalized name: phytosterols
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phytosterol capsules (2.0 g/d)
Study: 17085157
Drug: Sildenafil 100
Normalized name: sildenafil 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil 100 mg (single doses)
Study: 17085157
Drug: Sildenafil 100
Normalized name: sildenafil 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil 100 mg + Tamsulosin 0.4 mg (once daily for up to 14 days)
Study: 17085157
Drug: Sildenafil 100
Normalized name: sildenafil 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil 100 mg + Tamsulosin 0.4 mg
Study: 15248191
Drug: Verapamil (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (doses of 120, 180, 360, or 540 mg)
Study: 11483144
Drug: Adderall (mixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adderall (mixed amphetamine salts compound) at an average oral dose of 54 mg (administered in 2 daily doses)
Study: 7821320
Drug: Flecainide (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flecainide (2 mg.kg‐1 intravenous bolus in 10 min)
Study: 7821320
Drug: Dofetilide (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dofetilide (8 micrograms.kg‐1 maximum intravenous bolus in 15 min)
Study: 31462812
Drug: Fentanyl 3
Normalized name: FENTANYL 37.5MCG/HR PATCH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 3 μg/kg
Study: 31462812
Drug: Fentanyl 4
Normalized name: fentanyl 400 MCG Buccal Film
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 4 μg/kg
Study: 25521460
Drug: 0.1% tacrolimus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% tacrolimus ointment applied twice weekly
Study: 19339966
Drug: Pregnenolone (fixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregnenolone (fixed escalating doses to 500 mg/day)
Study: 16940442
Drug: Testosterone gel
Normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone gel (100 mg daily) + Depomedroxyprogesterone acetate (DMPA, 300 mg/3 months)
Study: 16940442
Drug: Testosterone gel
Normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone gel (100 mg daily) + Depomedroxyprogesterone acetate (DMPA, 300 mg/3 months) + Acyline (300 microg/kg every 2 weeks for 12 weeks)
Study: 22270204
Drug: 5% Acyclovir
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% Acyclovir cream
Study: 26150057
Drug: Paroxetine combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine combined with cognitive‐behavioral therapy
Study: 26150057
Drug: Paroxetine combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine combined with cognitive‐behavioral therapy and virtual reality exposure
Study: 8126502
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg entacapone
Study: 24925090
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg opicapone
Study: 27137718
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg opicapone
Study: 24925090
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg opicapone
Study: 23862255
Drug: Plain bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plain bupivacaine 10 mg with 25 mcg of fentanyl
Study: 23862255
Drug: Hyperbaric bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric bupivacaine 10 mg with 25 mcg of fentanyl
Study: 12485511
Drug: Nausea disintegrating
Normalized name: Pepto Nausea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nausea disintegrating buccal tablet (DBT) 0.1 mg before chemotherapy
Study: 12485511
Drug: Kytril tablet
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Kytril tablet 2 mg after chemotherapy
Study: 9802273
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (nitrendipine 10-40 mg/day, possibly with enalapril 5-20 mg/day, hydrochlorothiazide 12.5-25 mg/day)
Study: 7895926
Drug: Amoxicillin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin (1 g twice daily)
Study: 7895926
Drug: Omeprazole (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (40 mg twice daily for 14 days, then 20 mg once in the morning for 28 days)
Study: 2013669
Drug: Salbutamol 4
Normalized name: Salbutamol 400 microgram/actuation powder for inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol 4 mg by mouth
Study: 29119718
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone treatment (15 mg/d)
Study: 27960026
Drug: NTVC (Topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: NTVC (Topical vasodilating cream)
Study: 18338627
Drug: Oral Chinese
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Chinese materia medica (b. i. d)
Study: 18338627
Drug: Oral carboxymethyl
Normalized name: carboxymethyl fragment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral carboxymethyl liquor (control)
Study: 15847251
Drug: Telmisartan 40
Normalized name: telmisartan 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan 40 mg once daily for four weeks, increased to 80 mg if DBP >= 85 mmHg after four or eight weeks.
Study: 15847251
Drug: Telmisartan treatment
Normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telmisartan treatment
Study: 12774056
Drug: G‐CSF stimulated
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF stimulated stem cell donation
Study: 10420392
Drug: Microcrystalline chitosan
Normalized name: Chitosan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microcrystalline chitosan (MCCh; 3 capsules, each 400 mg b.i.d.)
Study: 2702229
Drug: Metered dose
Normalized name: Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metered dose inhaler use
Study: 27646508
Drug: Control (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (daily feedback without any incentive)
Study: 20051130
Drug: Pill placebo
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pill placebo (PBO)
Study: 23786536
Drug: Eplerenone (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eplerenone (100 mg/day) for 1 month
Study: 14636905
Drug: Rosuvastatin 20
Normalized name: rosuvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 20 mg/day titrated to 80 mg/day
Study: 14636905
Drug: Atorvastatin 20
Normalized name: atorvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 20 mg/day titrated to 80 mg/day
Study: 14636905
Drug: Rosuvastatin 40
Normalized name: rosuvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 40 and 80 mg
Study: 19064019
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (Rosuvastatin and Atorvastatin)
Study: 8626819
Drug: High calcium
Normalized name: Nutritional Supplement Oral Liquid [ENSURE HIGH CALCIUM]
Approvals — FDA: no, EMA: no, PMDA: no
Description: High calcium intake (60.4 ± 6.5 mmol/day [2414 ± 260 mg/day]; n = 13)
Study: 8626819
Drug: Usual calcium
Normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual calcium intake (20.4 ± 7.2 mmol/day [815 ± 289 mg/day]; n = 15)
Study: 1589234
Drug: Intranasal salmon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal salmon calcitonin (3 x 100 U/day)
Study: 1589234
Drug: Placebo (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (3 sprays)
Study: 2424102
Drug: Radiotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy plus weekly injection of bleomycin 15 mg and mitomycin C 4 mg
Study: 22765917
Drug: Aspirin (20mg/kg)
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin (20mg/kg) administered at 0h, 3h, or 24h after SE, followed by once daily treatment for 20 days
Study: 22765917
Drug: Aspirin (20mg/kg)
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin (20mg/kg) administered after SE
Study: 22765917
Drug: Aspirin (20mg/kg)
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin (20mg/kg) administered at 3h or 24h after SE
Study: 15828938
Drug: LyphoDerm +
Approvals — FDA: no, EMA: no, PMDA: no
Description: LyphoDerm + standard care (hydrocolloid dressing and compression therapy)
Study: 15828938
Drug: LyphoDerm +
Approvals — FDA: no, EMA: no, PMDA: no
Description: LyphoDerm + standard care (hydrocolloid dressing and compression therapy) in patients with enlarging ulcers
Study: 12424538
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human G‐CSF (Lenograstim) 263 micro g/day SC starting from day 12 (Group 1)
Study: 12424538
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human G‐CSF (Lenograstim) 263 micro g/day SC starting from day 17 (Group 2)
Study: 12424538
Drug: Historical control
Normalized name: typhus, historical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Historical control group (no G‐CSF)
Study: 24796970
Drug: Lisdexamfetamine (LDX)
DrugBank: Lisdexamfetamine (DB01255)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lisdexamfetamine (LDX) 30, 50, or 70 mg/day
Study: 19848574
Drug: Insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Insulin aspart applied with the FlexPen (IAFP)
Study: 19848574
Drug: Pulmonary human
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pulmonary human insulin applied with the Exubera device (HIEX)
Study: 27703286
Drug: Atracurium (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atracurium (0.5 mg/kg)
Study: 22584638
Drug: Cisatracurium (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisatracurium (0.15 mg/kg)
Study: 9576371
Drug: 1.1% amino
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.1% amino acid dialysis solution (Nutrineal)
Study: 29972210
Drug: Intervention group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention group (n=20) consuming a daily 200mL liquid juice containing 3000mg omega-3 PUFAs, 10μg vitamin D3, 150mg resveratrol, and 8g whey protein isolate
Study: 29972210
Drug: Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group (n=17) consuming a daily 200mL juice only
Study: 23876590
Drug: Imidafenacin (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imidafenacin (0.1 mg) twice daily
Study: 19788433
Drug: Capsulin (150U
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsulin (150U twice daily during repeat dosing)
Study: 16487438
Drug: Euthyroid group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Euthyroid group (L‐thyroxine plus placebo)
Study: 16487438
Drug: Low‐TSH group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low‐TSH group (L‐thyroxine)
Study: 1487561
Drug: Venlafaxine 25
Normalized name: venlafaxine 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine 25 mg
Study: 3161013
Drug: Ketanserin (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin (mean dose 71 mg/d)
Study: 31326345
Drug: Faecal microbiota
Approvals — FDA: no, EMA: no, PMDA: no
Description: Faecal microbiota transplantation (FMT) capsules (75 capsules over 3 days, each containing approximately 0.38 g of minimally processed donor stool)
Study: 31326345
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules (75 capsules over 3 days)
Study: 29953740
Drug: High-fat diet
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-fat diet and liraglutide treatment (HFL)
Study: 17888806
Drug: Problem-solving therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Problem-solving therapy plus usual care (PST-UC)
Study: 8313397
Drug: Brofaromine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brofaromine (150 mg/day)
Study: 4072939
Drug: Diltiazem (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (240 or 360 mg/day)
Study: 18957
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg oral carbuterol
Study: 18957
Drug: 35 mg
Normalized name: papain 35 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 35 mg ephedrine sulfate
Study: 25816713
Drug: atenolol (25-50
Approvals — FDA: no, EMA: no, PMDA: no
Description: atenolol (25-50 mg)
Study: 25816713
Drug: bisoprolol (2.5-5
Approvals — FDA: no, EMA: no, PMDA: no
Description: bisoprolol (2.5-5 mg)
Study: 8170529
Drug: both drugs
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: both drugs
Study: 23283255
Drug: Lidocaine 0.25
Normalized name: Bupivacaine Hydrochloride/Epinephrine/Lidocaine 0.25%-1 MG/1 ML-1% Injection Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 0.25 mg/kg
Study: 23283255
Drug: Lidocaine 0.5
Normalized name: LIDOCAINE 0.5% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 0.5 mg/kg
Study: 20723985
Drug: PAPP-A levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: PAPP-A levels ≥ 11.33 mIu/L
Study: 20723985
Drug: PAPP-A levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: PAPP-A levels < 11.33 mIu/L
Study: 20077989
Drug: Performance Intervention
Normalized name: Perform
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Performance Intervention (fostering daily mobility and activity)
Study: 17259484
Drug: Vildagliptin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vildagliptin (100 mg daily, divided doses)
Study: 17259484
Drug: Rosiglitazone (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone (8 mg daily, once daily)
Study: 15634825
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg of methadone
Study: 15634825
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg of morphine
Study: 15634825
Drug: 0.5 mL
Normalized name: ethanol 0.5 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mL of saline solution
Study: 12059047
Drug: AIT-082 (0.6,
Approvals — FDA: no, EMA: no, PMDA: no
Description: AIT-082 (0.6, 2.0, 6.0, and 20.0 mg/kg)
Study: 7733089
Drug: Nipradilol 6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nipradilol 6 mg twice a day (n = 14)
Study: 2209498
Drug: Antibiotic prophylaxis
Normalized name: STONE PROPHYLAXIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic prophylaxis (Cefotaxime 2 g i.v. 15 min before the procedure)
Study: 7421359
Drug: Quinine sulphate
Normalized name: Quinine sulphate
DrugBank: Quinine (DB00468)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quinine sulphate (300 mg capsule)
Study: 24063212
Drug: Tongjiang Granule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tongjiang Granule (TJG), 10 g each time, three times a day for 4 weeks
Study: 24063212
Drug: Omeprazole Tablet,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole Tablet, 20 mg each time, two times a day for 4 weeks
Study: 17950797
Drug: Coenzyme Q(10)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coenzyme Q(10) (200 mg/day)
Study: 21370966
Drug: Coenzyme Q(10)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coenzyme Q(10) (200 mg/day) vs Placebo
Study: 17722619
Drug: Rectal suppositories
Normalized name: Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal suppositories vitaprost forte
Study: 15104911
Drug: Cognitive-behavior therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavior therapy (CBT) delivered by videoconference
Study: 15104911
Drug: Cognitive-behavior therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavior therapy (CBT) delivered face-to-face
Study: 11361049
Drug: GW420867X 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: GW420867X 100 mg (fasted state)
Study: 11361049
Drug: GW420867X 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: GW420867X 100 mg (high-fat meal)
Study: 11361049
Drug: GW420867X 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: GW420867X 100 mg (normal fat meal)
Study: 7986784
Drug: Concentrated soya-bean-protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concentrated soya-bean-protein solution (isolate)
Study: 28805759
Drug: Long-acting pentoxifylline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting pentoxifylline (vasonite) in combined therapy
Study: 26125259
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin type A (BTX-A) treatment
Study: 26125259
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin type A (BTX-A) treatment combined with orthopedic joint brace
Study: 31562145
Drug: Oral medications
Normalized name: Medicated Shampoo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral medications
Study: 23042612
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT) - seven individual sessions concurrent with radiotherapy
Study: 23042612
Drug: Non-directive supportive
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-directive supportive counseling (SC) - seven individual sessions concurrent with radiotherapy
Study: 16462661
Drug: Cefpodoxime-proxetil (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefpodoxime-proxetil (200 mg bid for 5 days)
Study: 16462661
Drug: Amoxicillin-clavulanic acid
Normalized name: amoxicillin / clavulanate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin-clavulanic acid (1 g/125 mg bid for 8 days)
Study: 11760163
Drug: Ceftazidime (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime (2 g t.i.d.) + Amikacin (15 mg/kg/o.d.)
Study: 11760163
Drug: Cefepime (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefepime (2 g b.i.d.) + Amikacin (15 mg/kg/o.d.)
Study: 6412584
Drug: Droperidol 5
Normalized name: droPERidol 5 MG in 2 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droperidol 5 mg
Study: 6412584
Drug: Etomidate 10
Normalized name: metomidate 1000 mg in 1 g TOPICAL POWDER [Aquacalm]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etomidate 10 mg
Study: 24980836
Drug: 8-week yoga
Normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 8-week yoga intervention (n=15), consisting of a weekly 90-minute teacher-led class and a 40-minute daily session delivered by DVD